Jilin Aodong Pharmaceutical Group Co., Ltd. specializes in the manufacturing and marketing of pharmaceutical products. Besides, the group offers food products. Net sales break down by activity as follows: - sale of pharmaceutical products (89.4%); - sale of food products (6.8%); - other (3.8%). All sales are in China.

Employees

5,461

Sector

Pharmaceuticals

Calendar

08-29 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-08-27	CN¥18.68	+1.14%	16,763,532
26-08-26	CN¥18.47	+2.27%	19,329,893
26-08-25	CN¥18.06	+0.44%	7,787,116
26-08-24	CN¥17.98	+0.06%	9,857,556
26-08-21	CN¥17.97	-1.05%	10,788,241

End-of-day quote Shenzhen S.E.

More quotes

Annual profits - Rate of surprise

Company calendar

End-of-day quote Shenzhen S.E. 2026-08-25			5-day change	1st Jan Change
18.06 ^CNY	+0.44%		+0.44%	-7.53%

06-09	China Approves Aodong Subsidiary's Levocarnitine Injection	MT
05-21	Jilin Aodong Pharmaceutical Gets China Approval for Supplemental Registration of Heart Drug	MT

Market Cap	21.9B 3.26B 2.8B 2.62B 2.4B 4.52B 311B 4.53B 31.01B 12.12B 157B 12.23B 11.97B 519B	P/E 2024	13.1x	P/E 2025	9.57x
Enterprise Value	21.18B 3.15B 2.7B 2.53B 2.32B 4.37B 301B 4.38B 29.98B 11.72B 152B 11.83B 11.57B 502B	EV / Sales 2024	7.76x	EV / Sales 2025	9.49x
Free-Float	67.59%	Yield 2024	2.9%	Yield 2025	2.56%

06-09	China Approves Aodong Subsidiary's Levocarnitine Injection	MT
05-21	Jilin Aodong Pharmaceutical Gets China Approval for Supplemental Registration of Heart Drug	MT
05-12	Jilin Aodong Pharmaceutical Group Co., Ltd. Approves Final Cash Dividend on A Shares for the Year 2025, Payable on 08 July 2026	CI
04-29	Jilin Aodong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-20	Jilin Aodong Pharmaceutical's Attributable Profit Jumps 54% in 2025	MT
04-17	Jilin Aodong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-12	Aodong Pharmaceutical's Subsidiary Gets Nod to Market 10 Traditional Chinese Medicines	MT
01-26	Beijing Sun-Novo Pharmaceutical Research Co., Ltd. cancelled the acquisition of Jiangsu Langyan Life Technology Holdings Co., Ltd. from Li Qian, Ganzhou Langyi Investment Center (Limited Partnership) and Other shareholders.	CI
25-10-30	Jilin Aodong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-10-21	Aodong Pharmaceutical Gets China Supplementary Nod for Anti-Opioid Medication	MT
25-09-22	Jilin Aodong Pharmaceutical Group Co., Ltd. Approves Interim Cash Dividend on A Shares for 2025, Payable on October 22, 2025	CI
25-09-01	Jilin Aodong Pharmaceutical Group Co., Ltd. Proposes Interim Profit Distribution Plan for 2025	CI
25-08-29	Jilin Aodong Yanbian Pharmaceutical Co., Ltd. announced that it expects to receive CNY 134.393064 million in funding from Jilin Aodong Pharmaceutical Group Co., Ltd.	CI

1 day	+0.44%
1 week	+0.44%
Current month	-1.69%
1 month	+2.21%
3 months	+3.50%
6 months	-4.24%
Current year	-7.53%

Jilin Aodong Pharmaceutical Group Co., Ltd. Stock

Stocks

000623

CNE000000719

Pharmaceuticals

Valuation : Jilin Aodong Pharmaceutical Group Co., Ltd.

Chart: Jilin Aodong Pharmaceutical Group Co., Ltd.

Latest news : Jilin Aodong Pharmaceutical Group Co., Ltd.

Quotes and Performance

Price Extremes

Managers and Directors : Jilin Aodong Pharmaceutical Group Co., Ltd.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

1 week	17.82	18.25
1 month	17.61	18.54
Current year	16.36	20.93
1 year	16.36	22.08
3 years	12.49	22.08
5 years	12.49	22.08
10 years	12.49	29.43

Manager	Title	Age	Since
Shu Qin Guo CEO	Chief Executive Officer	63	2017-07-16
Kai Yang DFI	Director of Finance/CFO	49	2004-04-30
Shu Yuan Zhang DFI	Director of Finance/CFO	54	2007-06-17

Director	Title	Age	Since
Shu Qin Guo BRD	Director/Board Member	63	2000-01-31
Shu Yuan Zhang BRD	Director/Board Member	54	2020-07-16
Xiu Lin Li CHM	Chairman	74	2005-05-17

Date	Insider	Type	Main position	Quantity	% Market Cap.
11/25/25	An Ning Li	Buy		100	0.0000%
7/29/24	Xiu Lin Li	Buy	Chairman	350,000	0.0302%
7/29/24	Shu Qin Guo	Buy	Chief Executive Officer	320,000	0.0276%

	2024	2025
Net sales	2.61B 388M 333M 312M 286M 538M 37.1B 540M 3.7B 1.44B 18.7B 1.46B 1.43B 61.88B	2.34B 347M 298M 279M 256M 482M 33.18B 483M 3.31B 1.29B 16.72B 1.3B 1.28B 55.35B
Net income	1.55B 231M 198M 185M 170M 320M 22.05B 321M 2.2B 859M 11.11B 867M 848M 36.77B	2.4B 356M 306M 286M 262M 494M 34.04B 495M 3.39B 1.33B 17.15B 1.34B 1.31B 56.77B
Net Debt	-386M -57.42M -49.29M -46.15M -42.26M -79.61M -5.48B -79.83M -546M -214M -2.76B -216M -211M -9.15B	-724M -108M -92.47M -86.57M -79.27M -149M -10.29B -150M -1.03B -401M -5.19B -404M -396M -17.16B

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
JILIN AODONG PHARMACEUTICAL GROUP CO., LTD.	+0.44%	+0.44%	-12.63%	+9.45%	3.26B
ELI LILLY AND COMPANY	-1.12%	-5.49%	+60.19%	+112.43%	1,048B
JOHNSON & JOHNSON	-1.57%	-0.60%	+50.33%	+59.86%	640B
ABBVIE INC.	-1.81%	-1.41%	+24.07%	+75.98%	456B
ROCHE HOLDING AG	-0.56%	-3.65%	+38.66%	+39.65%	362B
NOVARTIS AG	+0.02%	-2.18%	+22.75%	+37.78%	295B
ASTRAZENECA PLC	-0.02%	+0.55%	+2.06%	+12.14%	255B
AMGEN INC.	-0.76%	+0.75%	+51.75%	+70.45%	236B
NOVO NORDISK A/S	+0.65%	-1.20%	-17.15%	-54.02%	204B
GILEAD SCIENCES, INC.	+0.52%	+3.78%	+30.67%	+93.68%	185B
Average	+0.13%	-0.49%	+25.07%	+45.74%	368.49B
Weighted average by Cap.	+0.17%	-1.92%	+38.51%	+65.79%